| 3.51 -0.08 (-2.23%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.02  |
1-year : | 5.63 |
| Resists | First : | 4.3 |
Second : | 4.82 |
| Pivot price | 3.82 |
|||
| Supports | First : | 3.46 |
Second : | 2.88 |
| MAs | MA(5) : | 3.78 |
MA(20) : | 3.79 |
| MA(100) : | 4.13 |
MA(250) : | 2.94  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 17.3 |
D(3) : | 39.7 |
| RSI | RSI(14): 37.1 |
|||
| 52-week | High : | 6.94 | Low : | 1.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ZNTL ] has closed below the lower bollinger band by 1.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 52.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.67 - 3.7 | 3.7 - 3.72 |
| Low: | 3.4 - 3.44 | 3.44 - 3.46 |
| Close: | 3.47 - 3.52 | 3.52 - 3.55 |
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Wed, 02 Sep 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Tue, 01 Sep 2026
Four new hires get rights to buy 269,000 Zentalis shares - Stock Titan
Mon, 31 Aug 2026
Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib (ZNTL) - Seeking Alpha
Thu, 13 Aug 2026
Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis - Stock Titan
Thu, 13 Aug 2026
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 95 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 21.7 (%) |
| Held by Institutions | 50.8 (%) |
| Shares Short | 5,970 (K) |
| Shares Short P.Month | 6,150 (K) |
| EPS | -1.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.2 % |
| Return on Equity (ttm) | -66.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -128 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -1.8 |
| PEG Ratio | 0 |
| Price to Book value | 1.36 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|